On the cusp of PhI, Angelman-focused biotech scores potential buyout deal from Ultragenyx
Ultragenyx has found a new rare disease to devote itself to, roping in a young upstart as it begins a long trek to a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
